Important pharmacokinetic parameters for individualization of 177Lu‐PSMA therapy: A global sensitivity analysis for a physiologically‐based pharmacokinetic model. Issue 2 (15th December 2020)
- Record Type:
- Journal Article
- Title:
- Important pharmacokinetic parameters for individualization of 177Lu‐PSMA therapy: A global sensitivity analysis for a physiologically‐based pharmacokinetic model. Issue 2 (15th December 2020)
- Main Title:
- Important pharmacokinetic parameters for individualization of 177Lu‐PSMA therapy: A global sensitivity analysis for a physiologically‐based pharmacokinetic model
- Authors:
- Hardiansyah, Deni
Kletting, Peter
Begum, Nusrat J.
Eiber, Matthias
Beer, Ambros J.
Pawiro, Supriyanto A.
Glatting, Gerhard - Abstract:
- Abstract : Purpose: The knowledge of the contribution of anatomical and physiological parameters to interindividual pharmacokinetic differences could potentially be used to improve individualized treatment planning for radionuclide therapy. The aim of this study was therefore to identify the physiologically based pharmacokinetic (PBPK) model parameters that determine the interindividual variability of absorbed doses (ADs) to kidneys and tumor lesions in therapy with 177 Lu‐labeled PSMA‐targeting radioligands. Methods: A global sensitivity analysis (GSA) with the extended Fourier Amplitude Sensitivity Test (eFAST) algorithm was performed. The whole‐body PBPK model for PSMA‐targeting radioligand therapy from our previous studies was used in this study. The model parameters of interest (input of the GSA) were the organ receptor densities [R0 ], the organ blood flows f, and the organ release rates λ . These parameters were systematically sampled NE times according to their distribution in the patient population. The corresponding pharmacokinetics were simulated and the ADs (model output) to kidneys and tumor lesions were collected. The main effect S i and total effect S Ti were calculated using the eFAST algorithm based on the variability of the model output: The main effect S i of input parameter i represents the reduction in variance of the output if the "true" value of parameter i would be known. The total effect S Ti of an input parameter i represents the proportion ofAbstract : Purpose: The knowledge of the contribution of anatomical and physiological parameters to interindividual pharmacokinetic differences could potentially be used to improve individualized treatment planning for radionuclide therapy. The aim of this study was therefore to identify the physiologically based pharmacokinetic (PBPK) model parameters that determine the interindividual variability of absorbed doses (ADs) to kidneys and tumor lesions in therapy with 177 Lu‐labeled PSMA‐targeting radioligands. Methods: A global sensitivity analysis (GSA) with the extended Fourier Amplitude Sensitivity Test (eFAST) algorithm was performed. The whole‐body PBPK model for PSMA‐targeting radioligand therapy from our previous studies was used in this study. The model parameters of interest (input of the GSA) were the organ receptor densities [R0 ], the organ blood flows f, and the organ release rates λ . These parameters were systematically sampled NE times according to their distribution in the patient population. The corresponding pharmacokinetics were simulated and the ADs (model output) to kidneys and tumor lesions were collected. The main effect S i and total effect S Ti were calculated using the eFAST algorithm based on the variability of the model output: The main effect S i of input parameter i represents the reduction in variance of the output if the "true" value of parameter i would be known. The total effect S Ti of an input parameter i represents the proportion of variance remaining if the "true" values of all other input parameters except for i are known. The numbers of samples NE were increased up to 8193 to check the stability (i.e., convergence) of the calculated main effects S i and total effects S Ti . Results: From the simulations, the relative interindividual variability of ADs in the kidneys (coefficient of variation CV = 31%) was lower than that of ADs in the tumors (CV up to 59%). Based on the GSA, the most important parameters that determine the ADs to the kidneys were kidneys flow ( S i = 0.36, S Ti = 0.43) and kidneys receptor density ( S i = 0.25, S Ti = 0.30). Tumor receptor density was identified as the most important parameter determining the ADs to tumors ( S i and S Ti up to 0.72). Conclusions: The results suggest that an accurate measurement of receptor density and flow before therapy could be a promising approach for developing an individualized treatment with 177 Lu‐labeled PSMA‐targeting radioligands. … (more)
- Is Part Of:
- Medical physics. Volume 48:Issue 2(2021)
- Journal:
- Medical physics
- Issue:
- Volume 48:Issue 2(2021)
- Issue Display:
- Volume 48, Issue 2 (2021)
- Year:
- 2021
- Volume:
- 48
- Issue:
- 2
- Issue Sort Value:
- 2021-0048-0002-0000
- Page Start:
- 556
- Page End:
- 568
- Publication Date:
- 2020-12-15
- Subjects:
- absorbed dose -- eFAST -- GSA -- PBPK model -- PSMA
Medical physics -- Periodicals
Medical physics
Geneeskunde
Natuurkunde
Toepassingen
Biophysics
Periodicals
Periodicals
Electronic journals
610.153 - Journal URLs:
- http://scitation.aip.org/content/aapm/journal/medphys ↗
https://aapm.onlinelibrary.wiley.com/journal/24734209 ↗
http://www.aip.org/ ↗ - DOI:
- 10.1002/mp.14622 ↗
- Languages:
- English
- ISSNs:
- 0094-2405
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 5531.130000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 21882.xml